← Leaderboards
Chinthalapally Rao
University Of Oklahoma Hlth Sciences Ctr
$10,981,534
Attributed
$10,981,534
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4M · FY2015–23$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$10,981,534 · 2
By mechanism
N01$10,981,534 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelPreventPre-ClinicalMalignant NeoplasmsChemopreventive AgentBiological MarkersToxic EffectCell ProliferationDosePreclinical Drug DevelopmentOverexpressionCancer EtiologyApoptosisPreventiveRattusCarcinogenesisPreclinical EfficacyImmune ResponseIn VivoPremalignantGenetically Engineered MousePharmaceutical PreparationsContractorMortality
Grant awards (16)
Base Title: PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint BiomarkersTask Order Title: Colorectal Cancer (CRC) Prevention by TPST-1495 in PIRC rat mod$1,140,397
N01 · FY2023 · CA · contact PI
Chemoprevention with mitochondria-targeted honokiol in mouse models of lung cancer: adenocarcinoma and squamous cell carcinoma$1,201,554
N01 · FY2022 · CA · contact PI
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE$1,046,094
N01 · FY2022 · CA · contact PI
TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT$982,258
N01 · FY2022 · CA · contact PI
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER$631,014
N01 · FY2022 · CA · contact PI
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERSTASK ORDER TITLE: PREVENTING FAP-CRC USING$143,327
N01 · FY2022 · CA · contact PI
PREVENT EFFICACY POOL: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM$911,531
N01 · FY2021 · CA · contact PI
PROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA$845,841
N01 · FY2021 · CA · contact PI
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER$482,513
N01 · FY2021 · CA · contact PI
TASK ORDER TITLE: PREVENTING COLORECTAL CANCER USING TRAIL-INDUCING ONC201 ALONE OR IN COMBINATION WITH NSAID$879,465
N01 · FY2020 · CA · contact PI
CHEMOPREVENTION WITH AEROSOLIZED LET-7 MICRORNA IN MOUSE MODELS OF NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA)$849,440
N01 · FY2019 · CA · contact PI
PROSTATE CANCER PREVENTION BY ASPIRIN AND/OR OTHER NSAIDS TORFP 2016-E03HHSN2612015000381PERIOD OF PERFORMANCE: 07/07/2016 - 03/06/2019$117,040
N01 · FY2019 · CA · contact PI
IGF::OT::IGF PREVENT Efficacy Task Order: Chemoprevention of Colorectal Cancer with Olmesartan Medoxomil$522,064
N01 · FY2017 · CA · contact PI
IGF::OT::IGF PROSTATE CANCER PREVENTION BY ASPIRIN AND/OR OTHER NSAIDS TORFP 2016-E03HHSN2612015000381PERIOD OF PERFORMANCE: 07/07/2016 - 03/06/2019$625,093
N01 · FY2016 · CA · contact PI
IGF::OT::IGF PREVENT EFFICACY: OPTIMIZATION OF GEM MODELS FOR HIGH-RISK COHORTS OF HUMAN PANCREATIC CYSTADENOMAS, IPMNS, AND PANINS PROGRESSION TO PDAC.$599,353
N01 · FY2015 · CA · contact PI
IGF::OT::IGF CONTRACT ORIENTATION AND KICK-OFF MEETINGPERIOD OF PERFORMANCE: 09/22/2015 - 12/31/2015$4,550
N01 · FY2015 · CA · contact PI